Randomized phase III trial of radiation treatment ± amifostine in patients with advanced-stage lung cancer

International Journal of Radiation Oncology Biology Physics

Volumn 51, Issue 4, 2001, Pages 915-922

  Antonadou, Dosia ^a   Coliarakis, Nikos ^a   Synodinou, Maria ^a   Athanassiou, Helen ^b   Kouveli, Athina ^c   Verigos, Cosmas ^a   Georgakopoulos, Grigoris ^c   Panoussaki, Katerina ^b   Karageorgis, Pantelis ^a   Throuvalas, Nicolas ^a  

^a METAXA CANCER HOSPITAL   (Greece)

^b Agioi Anargyri Hospital   (Greece)

^c Social Welfare Hospital   (Greece)

Author keywords

Amifostine; Lung cancer; Radiation therapy; Toxicity

Indexed keywords

PULMONARY DISEASES; RADIOTHERAPY; TOXICITY; TUMORS;

LUNG CANCER;

PATIENT TREATMENT;

AMIFOSTINE; ANTIEMETIC AGENT; ANTIHYPERTENSIVE AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESOPHAGITIS; FEMALE; FOLLOW UP; HUMAN; HYPOTENSION; LUNG CANCER; LUNG FIBROSIS; LUNG TOXICITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; PERFORMANCE; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT PLANNING;

ACUTE DISEASE; AMIFOSTINE; ESOPHAGITIS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREMEDICATION; RADIATION INJURIES; RADIATION PNEUMONITIS; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY DOSAGE;

EID: 0035889299     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)01713-8     Document Type: Article

References (37)

1. Chemotherapy of the lung cancer
2. The role of surgery in N2 lung cancer
3. The evolution of Radiation Therapy Oncology Group (RTOG) protocols for non small cell lung cancer
4. The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non small cell lung cancer (NSCLC)-Analysis of a Radiation Therapy Oncology Group (RTOG) protocol
5. Injury to the lung from cancer therapy clinical syndromes measurable endpoints and potential scoring systems
6. Pharmacokinetics of WR-2721
7. Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both; Its anti-cytotoxic and anti-mutagenic mechanisms of action
8. Mechanism of action of aminothiol radioprotectors
9. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non small cell lung cancer; Results of a phase II trial
10. Clinical study of the radioprotective effects of amifostine (YM08310, WR 2721) on chronic radiation injury
11. Acute radiation induced pulmonary damage. A clinical study on the response to fractionated radiation therapy
12. Radiation effects on the lung; Clinical features, pathology and imaging findings
13. Development of radiation pneumonitis
14. Radiation induced lung damage; Dose-time fractionation considerations
15. Effect of irradiation volume on lung damage in pigs
16. Estimation of overall pulmonary function after irradiation using dose-effect relations for local functional injury
17. Physical and biological predictors of changes as whole lung function following thoracic irradiation
18. Radiation pneumonitis following combined modality therapy for lung cancer; Analysis of prognostic factors
19. A randomized trial of induction chemotherapy plus high dose radiation versus radiation alone in stage III non small cell lung cancer
20. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60 to 79. 2Gy; Possible survival benefit with >60Gy in favorable patients with stage III non small cell lung carcinoma. Report of RTOG 83-11
21. Three dimensional treatment planning for lung cancer
22. 3D radiation treatment planning study for patients with carcinoma of the lung
23. The role of three dimensional functional lung imaging in radiation treatment planning. The functional dose volume histogram
24. Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR 2721
25. Amifostine (WR 2721) selectively protects human lung fibroblasts versus non small cell lung carcinoma cells from radiation damage
26. Biochemical determinants of the cytoprotective effect of amifostine
27. Radioprotective agents as modulators of cell and tissue radiosensitivity
28. Preliminary results of a pilot study using WR 2721 before fractionated irradiation of the head and neck to reduce salivary dysfunction
29. Amifostine preserves the salivary gland function during irradiation of the head and neck
30. Use of radiation with or without WR 2721 in advanced rectal cancer
31. Interim analysis of a randomized trial of radiation therapy of rectal cancer with/without WR 2721
32. Acute radiation induced pulmonary injury; Computed tomography evaluation
33. Radiation induced lung injury using a pig model. Evaluation by high resolution computed tomography
34. Physical and biological predictors of changes in whole lung function following thoracic irradiation
35. Physiological and radiographic assessment during the development of pulmonary radiation fibrosis
36. Effect of postoperative radiotherapy on changes in pulmonary function in patients with stage IV and IIIA lung carcinoma